NEW YORK, June 5 -The Institute for Systems Biology has signed onto do a new project with Lynx Therapeutics and IBM, to study response to infectious diseases in immune cells, the companies said today.
Under the agreement, Lynx will use its Massively Parallel Signature Sequencing, or MPSS technology to profile gene expression in the immune cells, in a study of macrophage inflammatory response to microbial infection.
IBM will provide the middleware for the data management and analysis, including licenses to the DB2 Universal Database, the WebSphere studio, and IBM's middleware tools and algorithms, which Lynx will incorporate into its IT platform, and will include in future sales of instruments.
IBM Research's computational biology center worked with Lynx and ISB on experimental design, and also will help with analysis of the data. IBM hopes to learn from the project what IT is required for computational systems biology research, the companies said.
The companies did not disclose the financial terms of the agreement.
This is the second collaboration between Lynx and ISB. Lynx is also using MPSS to study gene expression in prostate cancer for ISB, under an agreement begun in May 2002 and renewed for another year May 14.